Expanding Indications and Emerging Challenges in Endometrial Cancer

CME

Exploring the Endometrial Cancer Landscape: An Expert’s Roadmap to Expanding Indications, Emerging Challenges, and Equity Considerations

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: May 07, 2025

Expiration: November 06, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Based on recent demographic evidence, which of the following groups have the highest incidence and mortality from endometrial cancer?

2.

Patient Case 2: Young Black Woman Presents With Newly Diagnosed Endometrial Cancer



  • A 39-yr-old Black woman presents with newly diagnosed endometrial cancer

  • Biopsy demonstrates a grade 3 serous endometrial adenocarcinoma

    • Status post robotic-assisted total laparoscopic hysterectomy with bilateral salpingo-oophorectomy, bilateral pelvic sentinel lymphadenectomy




Pathology



  • Uterus, cervix, bilateral fallopian tubes and ovaries

    • Invasive endometrial adenocarcinoma, serous, FIGO grade 3

      • Tumor invades 8 mm out of 11 mm myometrial thickness, 73%

      • Lymph-vascular space invasion extensive

      • 1/2 SLN is positive





What molecular testing can help you best direct first-line therapy for this patient?

3.

How would you rate your level of confidence for counseling patients about predictive biomarkers and the underlying biology and rationale to help them with treatment selection for newly diagnosed advanced endometrial cancer and to evaluate family cancer risk?

4.

Patient Case 3: 56-Yr-Old White Woman Presents With Newly Diagnosed EC



  • 56-yr-old White woman referred to a gynecology oncologist presents with newly diagnosed EC

    • Obese with BMI 40 kg/m2

    • ECOG PS is 0



  • Endometrial biopsy shows grade 3, serous endometrial adenocarcinoma

  • CT scans demonstrate lung metastasis which are confirmed by biopsy

  • CA-125 is elevated (50 U/mL)

  • Biomarker testing demonstrates tumor is pMMR/MSS, HER2 negative

  • Patient is young and has goal of prolonging survival 

Considering FDA approvals, clinical guidelines, and most recent clinical trial data, what would be your recommended primary treatment for this patient with newly diagnosed EC and pMMR/MSS, HER2-negative status?